Investigational immunomodulatory therapies for COVID-19

M. Assi; K. M. Koshy; W. El Atrouni; K. Burke; M. Berg; A. Opardija; Z. Temesgen

doi:10.1358/dof.2021.46.9.3317238

Investigational immunomodulatory therapies for COVID-19

M. Assi, K. M. Koshy, W. El Atrouni, K. Burke, M. Berg, A. Opardija, Z. Temesgen

Infectious Diseases

Research output: Contribution to journal › Review article › peer-review

Abstract

A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov, and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.

Original language	English (US)
Pages (from-to)	711-729
Number of pages	19
Journal	Drugs of the Future
Volume	46
Issue number	9
DOIs	https://doi.org/10.1358/dof.2021.46.9.3317238
State	Published - Sep 2021

Keywords

Anti-IL-1 agents
Anti-IL-6 agents
CCR2 antagonists
CCR5 antagonists
COVID-19
Corticosteroids
GM-CSF
Immunomodulatory therapies
Interferons
Janus kinase inhibitors
Monoclonal antibodies

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2021.46.9.3317238

Cite this

@article{13f5df830c7e4ee1bbf207c50eb48fd1,

title = "Investigational immunomodulatory therapies for COVID-19",

abstract = "A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov, and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.",

keywords = "Anti-IL-1 agents, Anti-IL-6 agents, CCR2 antagonists, CCR5 antagonists, COVID-19, Corticosteroids, GM-CSF, Immunomodulatory therapies, Interferons, Janus kinase inhibitors, Monoclonal antibodies",

author = "M. Assi and Koshy, {K. M.} and {El Atrouni}, W. and K. Burke and M. Berg and A. Opardija and Z. Temesgen",

year = "2021",

month = sep,

doi = "10.1358/dof.2021.46.9.3317238",

language = "English (US)",

volume = "46",

pages = "711--729",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "9",

}

TY - JOUR

T1 - Investigational immunomodulatory therapies for COVID-19

AU - Assi, M.

AU - Koshy, K. M.

AU - El Atrouni, W.

AU - Burke, K.

AU - Berg, M.

AU - Opardija, A.

AU - Temesgen, Z.

PY - 2021/9

Y1 - 2021/9

N2 - A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov, and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.

AB - A large number of candidate drugs are undergoing evaluation for their potential to modulate the pathologic host immune response to SARS-CoV-2 infection. Clinical trial efficacy and safety data are slowly emerging for several of these agents. We provide a summary of candidate immunomodulatory agents, which are registered in ClinicalTrials.gov, and for which clinical data are available. We provide the rationale for their consideration for the treatment of COVID-19, as well as report on data available from the various clinical investigations of their efficacy and safety.

KW - Anti-IL-1 agents

KW - Anti-IL-6 agents

KW - CCR2 antagonists

KW - CCR5 antagonists

KW - COVID-19

KW - Corticosteroids

KW - GM-CSF

KW - Immunomodulatory therapies

KW - Interferons

KW - Janus kinase inhibitors

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85119159303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119159303&partnerID=8YFLogxK

U2 - 10.1358/dof.2021.46.9.3317238

DO - 10.1358/dof.2021.46.9.3317238

M3 - Review article

AN - SCOPUS:85119159303

SN - 0377-8282

VL - 46

SP - 711

EP - 729

JO - Drugs of the Future

JF - Drugs of the Future

IS - 9

ER -

Investigational immunomodulatory therapies for COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this